Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Net Margin (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed Net Margin for 2 consecutive years, with 47.48% as the latest value for Q2 2023.

  • Quarterly Net Margin rose 340245.0% to 47.48% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 1162.39% through Mar 2024, down 63008.0% year-over-year, with the annual reading at 453.92% for FY2022, 1397658.0% up from the prior year.
  • Net Margin hit 47.48% in Q2 2023 for Pasithea Therapeutics, down from 455.8% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 455.8% in Q1 2023 to a low of 3449.93% in Q2 2022.